From 2023 ASCO GI Cancers Symposium:
Phase III trial findings point to a significant overall survival improvement with regorafenib versus placebo for treatment-refractory locally advanced or metastatic gastric or oesophagogastric junction cancer...
Welcome to OncologyPRO – educational and scientific content for ESMO Members. Participants of some ESMO Meetings will have access to the Meeting resources section—limited to the meeting you attended. To gain full access to all the resources on this website, you must be an ESMO Member.
Please sign in using the username and password you created. To ensure a seamless browsing experience, we suggest that you sign in at the start of your visit.